Laminin 5 for growth of pancreatic islet cells

• US 5,672,361 A
• Filed: 03/29/1996
• Issued: 09/30/1997
• Est. Priority Date: 03/29/1996
• Status: Expired due to Fees

• Current Assignee: CyThera, Inc. (Vertex Pharmaceuticals Incorporated)
• Original Assignee: Desmos, Inc.
• Inventors: Halberstadt, Craig, Grzesiak, John J.
• Primary Examiner(s): Chan, Christina
• Assistant Examiner(s): VanderVegt, F. Pierre
• Application Number:
  US08/626,242
• Time in Patent Office: 550 Days
• Field of Search: 424/93.7, 424/520, 424/550, 424/562, 424/572, 424/556, 435/240.2, 435/240.21, 435/240.23, 435/402, 435/366, 435/350, 435/351, 435/352, 435/363, 514/3
• US Class Current: 424/556
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: C12N 2501/58 Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

A method of expanding the number of pancreatic islet cells for transplantation. Fetal islet cells are cultured in the presence of laminin 5 extracellular matrix, resulting in a significant increase in cell number after passaging in culture. The expanded islet cells contain insulin and respond to glucose challenge.

Claims

1. A method of growing cells of pancreatic islet-like cell clusters (ICCs), comprising the step of culturing said ICCs in culture media in contact with laminin 5, with the proviso that said laminin 5 is not rat laminin 5.

2. The method of claim 1, wherein said ICCs are from a mammal.

3. The method of claim 2, wherein said ICCs are from a human.

4. The method of claim 1, wherein said laminin 5 is selected from the group consisting of kalinin and epiligrin.

5. The method of claim 1, wherein said laminin 5 is the extracellular matrix obtainable from MCF 10A cells, ATCC CRL-10317.

6. The method of claim 1, wherein said laminin 5 is of human origin.

7. The method of claim 1, wherein said ICCs are expanded at least 5 fold and the expanded ICCs secrete insulin.

8. The pancreatic ICCs prepared in accordance with claim 1.

9. A method of treating Type I diabetes in a patient in need thereof, comprising the step of administering to said patient an effective insulin-producing amount of the ICCs of claim 8.

10. The method of claim 9, wherein said administering step is by implantation under the kidney capsule.

11. The method of claim 10, wherein said ICCs are placed in an immunoprotective barrier prior to said implantation.

12. The method of claim 9, wherein said administering step is by direct injection into the liver.

13. The method of claim 9, wherein said effective insulin-producing amount is between about 2×

10⁵ and about 8×

10⁵ ICCs.